Reify Health

Boston, Massachusetts, United States  All United States companies → Founded 2012
Biotech / Drug Discovery
Series D — $478M - $490.2M (Note: Discrepancies exist across sources)

About Reify Health

Reify Health is a healthcare AI company dedicated to accelerating and improving the accessibility of clinical trials. The company operates through two main entities: StudyTeam and Care Access. StudyTeam is a cloud-based software platform designed to optimize patient recruitment and enrollment, providing clinical trial teams with better visibility into the enrollment process and reducing manual work. This allows sponsors, Contract Research Organizations (CROs), and clinical research sites to focus their resources more effectively, leading to faster enrollment and stronger relationships between stakeholders.

Care Access, Reify Health’s other business entity, focuses on transforming clinical trial infrastructure by bringing research directly to more healthcare providers, communities, and patients wherever they are. This includes partnering with new-to-research physicians and clinical practices, particularly in underserved communities, to establish new research sites and expand access to clinical trials for diverse patient populations. Reify Health’s overall mission is to remove clinical trial operations as a bottleneck in delivering new therapies, aiming to make clinical trials predictable and accessible by 2030.

For physicians, Reify Health’s platforms offer tools to streamline the management of clinical trials, particularly in patient recruitment and enrollment. StudyTeam provides a centralized portal for these activities, aiming to simplify workflows and reduce the administrative burden often associated with clinical research. Care Access offers opportunities for physicians and their practices, especially those in underserved communities, to participate in clinical trials, thereby expanding access to research for a broader patient base. The company’s focus on decentralized trials and improving diversity in participation addresses critical health equity issues, as treatments can work differently across various racial and ethnic groups.

Focus Areas

clinical trial optimization patient recruitment patient enrollment decentralized clinical trials clinical trial software healthcare IT life sciences technology

Business Intelligence

Key InvestorsAltimeter Capital, Coatue, Dragoneer Investment Group, ICONIQ Growth, Adams Street Partners, Battery Ventures, Sierra Ventures, Asset Management Ventures, Rock Health
PartnershipsAmgen, AstraZeneca, Eli Lilly and Company, SubjectWell
TechnologyCloud-based software, mobile health platform, AI operating system (implied through AI tools for healthcare in prompt, but not explicitly stated as 'AI operating system' in search results)

What Physicians Need to Know

Specialization
Reify Health specializes in cloud-based software and decentralized research solutions that accelerate and optimize clinical trials. Their core focus is on streamlining patient recruitment and enrollment, and making clinical research more accessible.
Key Products
They operate through two main entities: StudyTeam, a cloud-based platform for optimizing patient recruitment and enrollment, and Care Access, a decentralized research organization that brings clinical trial infrastructure directly to patients, healthcare providers, and communities.
Key Differentiators
Reify Health differentiates itself by providing end-to-end visibility into the patient funnel, enabling faster and more predictable enrollment. They also focus on expanding access to clinical trials for diverse patient populations and underserved communities through decentralized trial models, including mobile site vehicles.
Technology Stack
Reify Health utilizes modern web technologies, with a technical foundation built on Clojure and ClojureScript for both front-end and back-end development. This allows for rapid iteration, efficient development, and a single language across the application.
Impact & Reach
StudyTeam is used by top biopharma companies (including AstraZeneca and Eli Lilly) and thousands of research sites across over 100 countries, demonstrating significant global reach and impact on accelerating clinical trial enrollment.
Physician Tip

For physicians, Reify Health's platforms, particularly StudyTeam, can significantly reduce the administrative burden associated with patient recruitment and enrollment in clinical trials. It offers a centralized platform to manage patients across multiple trials and sponsors, eliminating redundant work and providing real-time insights into enrollment progress. Care Access can also enable physicians in underserved communities or those new to research to participate in clinical trials by bringing the necessary infrastructure directly to their patients. This can lead to faster access to potentially life-saving therapies for their patients and contribute to more diverse and representative clinical trial outcomes.

Reify Health's technology foundation is designed to integrate seamlessly with other solutions, aiming to connect the complex workflows of various clinical trial stakeholders, including research sites, sponsors, patients, and technology vendors, on a common platform.

Products by Reify Health

No products listed for this company yet. Know of one? Suggest it →

What the Web Says

Reify Health, known for its StudyTeam platform, aims to streamline clinical trial operations and improve patient access to studies. Employee reviews indicate a company with a strong mission and intelligent, supportive colleagues, though some recent feedback points to concerns about management decisions and job security. The company utilizes advanced technology like Clojure in its development.

Overall: Mixed

Strengths

  • Strong company mission to improve healthcare.
  • Intelligent and supportive colleagues.
  • Positive and collaborative work environment.
  • Good work-life balance.
  • Transparent culture with open leadership communication.
  • Opportunity to work with interesting technologies like Clojure.

Limitations

  • Concerns about management decisions.
  • Issues with job security, including layoffs.
  • Organization described as poorly run by some.
  • Rapid growth leading to some instability.
  • Interview process can be long.
  • Some employees feel overqualified or that explanations are sometimes too lengthy for colleagues.

Based on reviews from: Indeed.com, Comparably, Reddit, Reify Health Website

Last updated: 2026-09-11

Videos

News, demos, and interviews about Reify Health.

Loading videos...

Videos load interactively. If none appear, search YouTube for Reify Health →

View all on YouTube

Press & Coverage

Reify Health Press Release
Reify Health Raises $220 Million to Bridge the Diversity Gap in Clinical Trials
Reify Health announced a $220M Series D funding round to accelerate efforts in improving diversity and representation in clinical trial participation. The company also launched the BRIDGE initiative to understand and overcome barriers for underrepresented minority groups in clinical trials.
2022-04
Built In Boston
Boston-Based Reify Health Raises $220M, Doubles Valuation to $4.8B
Reify Health secured a $220 million Series D round, increasing its valuation to $4.8 billion, to advance its clinical optimization software and enhance diversity in clinical trials. This funding follows a Series C raise eight months prior.
2022-04
pharmaphorum
Financing pushes value of clinical trial tech firm Reify to $4.8bn
Reify Health's fourth-round financing of $220 million boosted its valuation to $4.8 billion, with plans to launch the BRIDGE initiative to address diversity and inclusion in clinical trials.
2022-04
Business Wire
Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials
Reify Health announced a $220 million Series C funding round, valuing the company at $2.2 billion, to accelerate clinical trial timelines through its StudyTeam and Care Access entities. The funding will support the expansion of both business units.
2021-08
Built In Boston
As More Clinical Trials Go Remote, New Unicorn Reify Health Raises $220M
Reify Health, a Boston-based startup digitizing clinical trials, secured $220 million in Series C funding, reaching a valuation of $2.2 billion. The company's platforms, StudyTeam and Care Access, aim to improve patient recruitment and enable decentralized trials.
2021-08
ICONIQ (Medium)
Reify Health: Building and delivering the future of clinical trials
ICONIQ Growth partnered with Reify Health in its Series C financing, recognizing the company's mission to accelerate trial delivery and enable broader patient participation through its StudyTeam and Care Access platforms.
2021-08
Business Wire
Reify Health Announces Global Expansion of StudyTeam to Over 2,700 Clinical Research Sites
Reify Health announced the expansion of its StudyTeam platform to over 2,700 clinical research sites in 100 countries worldwide. This expansion aims to provide effective solutions for managing patient recruitment and enrollment, reducing manual work for sites.
2021-01
Clinical Trials Arena
Reify Health extends StudyTeam platform availability for clinical trials
Reify Health made its patient enrollment performance management platform, StudyTeam, available to clinical research sites in 100 countries. This expansion highlights Reify Health's commitment to empowering research site staff and streamlining recruitment.
2021-01

Frequently Asked Questions

Reify Health offers StudyTeam and Care Access. StudyTeam is a cloud-based platform that helps optimize patient recruitment and enrollment in clinical trials, aiming to digitize manual work and accelerate tasks. Care Access provides decentralized clinical trial infrastructure, bringing research directly to patients and healthcare providers, which can expand access to trials in underserved communities.
While specific details on Reify Health's AI compliance with HIPAA were not explicitly found, the company's StudyTeam platform is designed to enable secure and real-time communication of critical enrollment information between research sites and sponsors. Generally, integrating AI in healthcare requires navigating legal, compliance, professional liability, and privacy and security implications, with a strong emphasis on data privacy and security.
Specific pricing models for Reify Health's products for healthcare providers and administrators are not publicly detailed in the search results. However, StudyTeam offers a technology platform that is free for sites and paid for sponsors. Generally, healthcare software companies often use modular pricing that scales with the workflows needed.
Reify Health's StudyTeam platform was developed with extensive research involving site staff and designed by current and former Research Coordinators to ensure it fits into existing workflows. This indicates a focus on user-friendly design and integration. Additionally, Reify Health aims to empower research sponsors, doctors, and research coordinators to focus more on successful clinical research.
Reify Health has significant partnerships within the healthcare and biopharma industries. They work with half of the global top 20 biopharma sponsors, including AstraZeneca, Amgen, and Eli Lilly and Company. They also partner with thousands of research sites globally and have collaborated with organizations like SubjectWell to streamline patient recruitment.
Reify Health appears to be financially stable and growing. The company was founded in 2012 and reached a $4.8 billion valuation in 2022 after a $220 million Series D funding round. They have raised a total of $478 million in funding across seven rounds. In 2025, Reify Health's revenue reached $189 million.
While the provided information doesn't explicitly detail Reify Health's approach to algorithmic bias or human oversight in their AI, their mission is to make clinical trials more accessible and efficient. The company focuses on expanding access to clinical trials for diverse patient populations, which indirectly addresses concerns about representation in research data that could lead to bias.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.